From Cancer survivors to new drugs.

We want every patient to become an Outlier.

While oncology players usually study the biology of the 97% of patients who die from the most lethal Cancers,

We focus on the rare miraculous 3% of patients who do survive.

They are the Outliers.

5,000 to 7,500 patients per year

survive to the most lethal Cancers.

5,000 to 7,500 patients per year

survive to the most lethal Cancers.

We are a TechBio company co-created with leading international oncology centers and researchers.

International network of Investigation Centres

Cure 51 focuses on patients who have survived some of the most lethal Cancers.

Including Metastatic Pancreatic Ductal Adenocarcinoma, Glioblastoma and Extensive stage Small Cell Lung Cancer.

Patients with Cancer who respond exceptionally well to therapy may have molecular changes in their tumors that explain their response.  

 A comprehensive analysis of this group that identified these changes may help to contribute to the development of potential new treatments.

Our proprietary Discovery Platform will be the hub for organizing, analyzing and discovering novel therapeutic targets.

Our scientific leaders

Our Clinical Steering Committee  
includes world-renowned oncologists.

FABRICE ANDRÉ, MD, PhD

Head of Steering Committee

President Elect ESMO
Research Director @Institut Gustave Roussy, Villejuif

ERIC SOLARY, MD, PhD

Head of Science

President of the Scientific Council ARC, Paris

RONY WEITZEN, MD

Head of Unit Sheba Medical Center, Tel Aviv

SOLANGE PETERS, MD, PhD

Head of Medical Oncology CHUV Lausanne

STEPHAN FRÖHLING, MD, PhD

Head of Translational Medical Oncology DKFZ

Director NCT Heidelberg

JOSEP TABERNERO, MD, PhD

Director Vall d’Hebron Institute of Oncology, Barcelona

Executive board – ESMO

RAVID STRAUSSMAN, MD, PhD

Principal Investigator Weizmann Institute of Science – Tel Aviv

OLIVIER ELEMENTO, PhD

Director of Englander Institute for Precision Medicine at Cornell University, New York

JEAN-YVES BLAY, MD, PhD

President Unicancer

Director Centre Léon Bérard, Lyon

ULRICH KEILHOLZ, MD, PhD

Director – Charité Comprehensive Center Berlin

RONIT SATCHI-FAINARO, PhD

Head, Cancer Research and Nanomedicine Laboratory – Tel Aviv